CDSCO IRB submission SOP – Clinical Research Made Simple

SOP for EC/IRB Amendments and Notifications

digi — Fri, 08 Aug 2025 05:00:02 +0000

SOP for EC/IRB Amendments and Notifications

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Amendments-and-Notifications”
},
“headline”: “SOP for Ethics Committee and IRB Amendments and Notifications”,
“description”: “This SOP defines standardized procedures for submitting amendments and notifications to Ethics Committees and IRBs, ensuring compliance with ICH GCP, WHO, FDA, EMA, and CDSCO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC/IRB Amendments and Notifications

Department	Clinical Research
SOP No.	CR/ETH/008/2025
Supersedes	NA
Page No.	1 of 20
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Purpose

The purpose of this SOP is to provide guidance on the preparation, submission, and follow-up of amendments and notifications to Ethics Committees (EC) and Institutional Review Boards (IRB). It ensures compliance with international (ICH GCP, WHO) and national (FDA, EMA, CDSCO) requirements for safeguarding trial participants and maintaining ethical oversight.

Scope

This SOP applies to sponsors, investigators, regulatory affairs staff, and quality assurance teams engaged in submitting protocol amendments, administrative changes, and safety-related notifications to EC/IRBs for clinical trials.

Responsibilities

Principal Investigator (PI): Initiates protocol amendments and notifies EC/IRB of site-level changes.
Regulatory Affairs Manager: Compiles and submits amendment packages and notifications to EC/IRBs.
Clinical Research Associate (CRA): Ensures sites implement approved changes and maintains amendment records.
Quality Assurance Officer: Reviews amendment documents for compliance before submission.
Head of Clinical Research: Provides final approval before amendment submission.

Accountability

The Regulatory Affairs Head is accountable for ensuring that amendments and notifications are submitted promptly, accurately, and in accordance with regulatory requirements. Non-compliance may result in trial delays, ethical non-conformance, or regulatory findings.

Procedure

1. Identification of Amendment or Notification Requirement
Determine whether change qualifies as substantial (requiring EC/IRB approval) or non-substantial (requiring notification only).
Document reason for amendment or notification in Amendment Request Form.

2. Preparation of Amendment/Notification Package
Update trial documents such as protocol, informed consent forms, or recruitment materials.
Include cover letter, amendment description, justification, and impact analysis.
Compile supporting data (safety reports, investigator’s brochure updates, etc.).

3. Internal Review
QA verifies accuracy, completeness, and compliance with guidelines.
Head of Clinical Research approves final package.

4. Submission to EC/IRB
Submit amendment/notification electronically or in hard copy as per EC/IRB requirements.
Obtain acknowledgment of receipt.
Record submission details in Communication Log.

5. Follow-up and Approval Tracking
Track review and approval timelines in Amendment Tracker.
Respond promptly to EC/IRB queries.
File final approval letters in Trial Master File (TMF).

6. Implementation
Ensure approved changes are implemented at sites.
Provide training for site staff if amendments affect trial conduct.

Abbreviations

SOP: Standard Operating Procedure
EC: Ethics Committee
IRB: Institutional Review Board
PI: Principal Investigator
CRA: Clinical Research Associate
QA: Quality Assurance
TMF: Trial Master File

Documents

Amendment Request Form (Annexure-1)
Amendment Tracker (Annexure-2)
EC/IRB Communication Log (Annexure-3)

References

ICH E6(R2) Good Clinical Practice
US FDA 21 CFR Part 56 – IRB Requirements
EMA Clinical Trial Regulation (EU No. 536/2014)
WHO Guidelines for Ethics Committees
CDSCO Clinical Trial Rules, India (2019)

Version: 1.0

Approval Section

Prepared By	Rajesh Kumar, Regulatory Affairs Specialist
Checked By	Sunita Reddy, QA Officer
Approved By	Dr. Anil Sharma, Head of Clinical Research

Annexures

Annexure-1: Amendment Request Form

Date	Protocol No.	Description	Reason	Initiated By
01/09/2025	CTP-2025-02	Change in visit schedule	Operational feasibility	Dr. Meera Joshi

Annexure-2: Amendment Tracker

Amendment No.	Date Submitted	EC/IRB	Status	Remarks
01	05/09/2025	Metro EC	Approved	Conditions: update ICF

Annexure-3: EC/IRB Communication Log

Date	EC/IRB	Query	Response	Responsible Person
12/09/2025	Metro EC	Clarify recruitment materials	Submitted revised flyer	Rajesh Kumar

Revision History

Revision Date	Revision No.	Revision Details	Reason for Revision	Approved By
26/08/2025	00	Initial version	New SOP creation	Head, Clinical Research

For more SOPs visit: Pharma SOP

SOP for EC/IRB Continuing Review and Renewals

digi — Thu, 07 Aug 2025 15:52:32 +0000

SOP for EC/IRB Continuing Review and Renewals

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-EC-IRB-Continuing-Review-and-Renewals”
},
“headline”: “SOP for Ethics Committee and IRB Continuing Review and Renewals”,
“description”: “This SOP outlines the regulatory-compliant process for EC/IRB continuing review and renewals to maintain ethical oversight of clinical trials, aligned with ICH GCP, FDA, EMA, CDSCO, and WHO guidelines.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for EC/IRB Continuing Review and Renewals

Department	Clinical Research
SOP No.	CR/ETH/007/2025
Supersedes	NA
Page No.	1 of 21
Issue Date	26/08/2025
Effective Date	01/09/2025
Review Date	01/09/2026

Purpose

The purpose of this SOP is to describe the process for conducting Ethics Committee (EC) and Institutional Review Board (IRB) continuing reviews and renewals of clinical trials. This ensures ongoing ethical oversight, participant protection, and compliance with ICH-GCP, WHO, FDA, EMA, and CDSCO regulatory requirements.

Scope

This SOP applies to all clinical research staff, investigators, regulatory affairs personnel, and quality assurance officers involved in the preparation, submission, and follow-up of EC/IRB continuing review and renewal applications for clinical trials.

Responsibilities

Principal Investigator (PI): Prepares progress reports and renewal documents for submission to EC/IRB.
Regulatory Affairs Manager: Coordinates submissions and ensures compliance with regional requirements.
Clinical Research Associate (CRA): Collects site-level data and ensures accuracy of reports.
Quality Assurance Officer: Reviews documents for completeness and compliance with applicable guidelines.
Head of Clinical Research: Approves submissions before dispatch to EC/IRB.

Accountability

The Regulatory Affairs Head is accountable for ensuring that continuing review and renewal applications are submitted on time, complete, and compliant. Failure to maintain approvals may result in trial suspension or regulatory non-compliance.

Procedure

1. Identification of Renewal Requirement
Determine the renewal due date based on EC/IRB initial approval letter.
Notify PI and study team at least 60 days before renewal deadline.

2. Preparation of Renewal Package
Include protocol progress report, enrollment status, safety summary (AE/SAE reports), deviations, amendments since last approval, and updated Investigator’s Brochure if applicable.
Ensure all documents are updated and signed by responsible personnel.

3. Internal Review
QA reviews renewal package for completeness.
Head of Clinical Research reviews and approves the package.

4. Submission to EC/IRB
Submit renewal package in electronic or paper form as per EC/IRB requirements.
File proof of submission in Regulatory Communication Log.

5. Approval Tracking
Maintain EC/IRB Renewal Tracker with submission and approval dates.
Follow up until approval is received.

6. Post-Approval Implementation
Communicate approval to trial sites and sponsor.
Implement EC/IRB conditions, if any, prior to continuing the trial.